Abstract
Despite the well-established role of oncogenic RAS in promoting tumor formation, whether and how wild-type (WT) Ras inhibits tumorigenesis under physiological conditions remains controversial. Here, we show that in a fraction of endogenous oncogenic Kras-induced hematopoietic malignancies, including acute T-cell lymphoblastic leukemia/lymphoma (T-ALL) and myeloproliferative neoplasm (MPN), WT Kras expression is lost through epigenetic or genetic mechanisms. Using conditional KrasG12D/− mice, we find that WT Kras deficiency promotes oncogenic Kras-induced MPN, but not T-ALL, in a cell-autonomous manner. Loss of WT Kras rescues oncogenic Kras-mediated hematopoietic stem cell depletion and further enhances granulocyte-macrophage colony-stimulating factor signaling in myeloid cells expressing oncogenic Kras. Quantitative signaling studies reveal that oncogenic Kras but not oncogenic Nras leads to cross-activation of WT Ras, whereas loss of WT Kras further promotes the activation of all Ras isoforms. Our results demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms.
Similar content being viewed by others
References
Boguski MS, McCormick F . Proteins regulating Ras and its relatives. Nature 1993; 366: 643–654.
Quilliam LA, Rebhun JF, Castro AF . A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 2002; 71: 391–444.
Shannon K . The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr Opin Hematol 1995; 2: 305–308.
Bos JL . ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–4689.
Cohen JB, Levinson AD . A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature 1988; 334: 119–124.
Finney RE, Bishop JM . Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 1993; 260: 1524–1527.
Bremner R, Balmain A . Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407–417.
Buchmann A, Ruggeri B, Klein-Szanto AJ, Balmain A . Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991; 51: 4097–4101.
Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001; 29: 25–33.
Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63–73.
Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov 2013; 3: 993–1001.
Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514–4518.
Wang JY, Liu YG, Li ZY, Du J, Ryu MJ, Taylor PR et al. Endogenous oncogenic Nras mutation leads to aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991–6002.
Wang JY, Liu YG, Li ZY, Wang ZD, Tan LX, Ryu MJ et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood 2011; 118: 368–379.
Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov 2014; 4: 1418–1429.
Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009; 113: 1304–1314.
Zhang J, Lodish HF . Identification of K-ras as the major regulator for cytokine-dependent Akt activation in erythroid progenitors in vivo. Proc Natl Acad Sci USA 2005; 102: 14605–14610.
Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA et al. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem 2013; 288: 18219–18227.
Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009; 7: e59.
Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC et al. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 2013; 27: 754–757.
Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014; 124: 2762–2773.
Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528–538.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.
Staffas A, Karlsson C, Persson M, Palmqvist L, Bergo MO . Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. Leukemia 2014; 29: 1032–1040.
Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J et al. Loss of Dnmt3a and endogenous Kras cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia 2015; 29: 1847–1856.
Boggs DR . The total marrow mass of the mouse: a simplified method of measurement. Am J Hematol 1984; 16: 277–286.
Acknowledgements
We thank the University of Wisconsin Carbone Comprehensive Cancer Center (UWCCC) for use of its Shared Services to complete this research. This work was supported by R01 grants R01CA152108 and R01HL113066, and a Scholar Award from the Leukemia & Lymphoma Society to JZ and R01 GM096060 to YX. This work was also supported in part by NIH/NCI P30 CA014520—UW Comprehensive Cancer Center Support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kong, G., Chang, YI., Damnernsawad, A. et al. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. Leukemia 30, 1542–1551 (2016). https://doi.org/10.1038/leu.2016.40
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.40
- Springer Nature Limited
This article is cited by
-
KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo
Nature Communications (2024)
-
Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth
Nature Cell Biology (2023)
-
Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma
Nature Communications (2023)
-
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Nature Communications (2022)
-
Ras isoform-specific expression, chromatin accessibility, and signaling
Biophysical Reviews (2021)